Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 11/20 | 0.83 |
| ▸ | HTR2C | P28335 | 3/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.74 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.74 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.62 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318264 | 0.93 | OPRK1 (0.72) | OPRK1HTR2CADORA3SLC6A3HTR1A | |
| SCHEMBL12315517 | 0.91 | OPRK1 (0.73) | OPRK1HTR2CADORA3SLC6A3HTR1A | |
| SCHEMBL318707 | 0.81 | HSD17B10 (0.65) | OPRK1HTR2COPRM1AVPR1AOPRL1 | |
| SCHEMBL12340733 | 0.81 | OPRK1 (0.58) | OPRK1HTR2CADORA3SLC6A3HTR1A | |
| SCHEMBL318858 | 0.81 | CCR5 (0.75) | OPRK1HTR2CADORA3SLC6A3HTR1A | |
| SCHEMBL318843 | 0.80 | OPRK1 (0.56) | OPRK1HTR2CADORA3SLC6A3HTR1A | |
| SCHEMBL13925107 | 0.80 | OPRK1 (0.59) | OPRK1HTR2CADORA3SLC6A3HTR1A | |
| SCHEMBL21634299 | 0.79 | HSD17B10 (0.62) | OPRK1HTR2COPRM1AVPR1AOPRL1 | |
| SCHEMBL1761014 | 0.79 | OPRL1 (0.64) | OPRK1HTR2COPRM1AVPR1AOPRL1 | |
| SCHEMBL21634315 | 0.78 | HSD17B10 (0.60) | OPRK1HTR2COPRM1AVPR1AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2582701-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011160084-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | OPRK1 29/4885HTR2C 36/4885ADORA3 21/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | OPRK1 29/4885HTR2C 36/4885ADORA3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.